BRPI0414592A - antagonistas de receptores de trombina - Google Patents

antagonistas de receptores de trombina

Info

Publication number
BRPI0414592A
BRPI0414592A BRPI0414592-5A BRPI0414592A BRPI0414592A BR PI0414592 A BRPI0414592 A BR PI0414592A BR PI0414592 A BRPI0414592 A BR PI0414592A BR PI0414592 A BRPI0414592 A BR PI0414592A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
thrombin receptor
thrombin
trombine
series
Prior art date
Application number
BRPI0414592-5A
Other languages
English (en)
Inventor
Samuel Chackalamannil
Mariappan V Chelliah
Yan Xia
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0414592A publication Critical patent/BRPI0414592A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"ANTAGONISTAS DE RECEPTORES DE TROMBINA". A invenção refere-se a uma série de compostos representados pelas fórmulas estruturais
BRPI0414592-5A 2003-09-25 2004-09-23 antagonistas de receptores de trombina BRPI0414592A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/671,216 US7488742B2 (en) 2000-06-15 2003-09-25 Thrombin receptor antagonists
PCT/US2004/031495 WO2005030712A2 (en) 2003-09-25 2004-09-23 Thrombin receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0414592A true BRPI0414592A (pt) 2006-11-07

Family

ID=34393462

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414592-5A BRPI0414592A (pt) 2003-09-25 2004-09-23 antagonistas de receptores de trombina

Country Status (21)

Country Link
US (3) US7488742B2 (pt)
EP (1) EP1663965B1 (pt)
JP (1) JP4694490B2 (pt)
KR (1) KR20060128848A (pt)
CN (1) CN101128457A (pt)
AR (1) AR045809A1 (pt)
AU (1) AU2004276327B2 (pt)
BR (1) BRPI0414592A (pt)
CA (1) CA2540163C (pt)
CO (1) CO5680428A2 (pt)
EC (1) ECSP066455A (pt)
IL (1) IL174538A0 (pt)
MX (1) MXPA06003379A (pt)
MY (1) MY143834A (pt)
NO (1) NO20061797L (pt)
PE (1) PE20050471A1 (pt)
RU (1) RU2367660C9 (pt)
SG (1) SG147466A1 (pt)
TW (1) TWI331608B (pt)
WO (1) WO2005030712A2 (pt)
ZA (1) ZA200602448B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
JP4558331B2 (ja) * 2002-04-16 2010-10-06 シェーリング コーポレイション 三環式トロンビンレセプターアンタゴニスト
WO2004113300A1 (ja) * 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. 新規三環性複素環化合物
MY143987A (en) * 2004-05-28 2011-07-29 Schering Corp Constrained himbacine analogs as thrombin receptor antagonists
JP2008510726A (ja) * 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
AU2005294265A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
EP1802609A2 (en) * 2004-10-08 2007-07-04 Schering Corporation Thrombin receptor antagonists
ES2459742T3 (es) 2004-12-22 2014-05-12 Ono Pharmaceutical Co., Ltd. Compuesto tricíclico y uso del mismo
EP2206697B1 (en) 2005-01-14 2011-10-26 Schering Corporation Exo- and diastereo-selective syntheses of himbacine analogs
US7776889B2 (en) * 2005-03-31 2010-08-17 Schering Corporation Spirocyclic thrombin receptor antagonists
WO2007075808A2 (en) * 2005-12-20 2007-07-05 Schering Corporation Methods for preventing and/or treating a cell proliferative disorder
WO2007075809A2 (en) * 2005-12-22 2007-07-05 Schering Corporation Oxazoloisoquinoline derivatives as thrombin receptor antagonists
BRPI0620641A2 (pt) * 2005-12-22 2011-11-16 Schering Corp usos de compostos antagonistas de receptor de trombina na profilaxia de complicações de cirurgia cardiopulmonar
KR20080104352A (ko) * 2006-03-29 2008-12-02 쉐링 코포레이션 트롬빈 수용체 길항제로서 유용한 모노사이클릭 및 비사이클릭 힘바신 유도체
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
US8003803B2 (en) * 2006-04-13 2011-08-23 Schering Corporation Fused ring thrombin receptor antagonists
EP2032560B1 (en) 2006-06-29 2013-05-01 Merck Sharp & Dohme Corp. Substituted bicyclic and tricyclic thrombin receptor antagonists
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
DE102006036023A1 (de) * 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
AU2007305269A1 (en) * 2006-10-04 2008-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
EP2120879A2 (en) * 2006-12-22 2009-11-25 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
BRPI0809095A2 (pt) * 2007-03-23 2014-09-09 Schering Corp Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina
BRPI0907487A2 (pt) * 2008-02-05 2015-07-14 Sanofi Aventis Sais de triazólio como inibidores de par1, produção dos mesmos e uso como medicamentos
SI2242740T1 (sl) 2008-02-05 2013-03-29 Sanofi SF5-derivati kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila
CN101981034B (zh) * 2008-02-05 2013-08-14 赛诺菲-安万特 作为par1抑制剂的三唑并哒嗪、其制备及其制备药物的用途
HRP20131049T1 (hr) 2009-06-04 2013-12-06 Merck Sharp & Dohme Corp. Aktivni metabolit antagonista trombinskog receptora
AU2010259003A1 (en) 2009-06-08 2011-11-10 Merck Sharp & Dohme Corp. A thrombin receptor antagonist and clopidogrel fixed dose tablet
WO2011128421A1 (de) 2010-04-16 2011-10-20 Sanofi Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren
WO2011128420A1 (de) 2010-04-16 2011-10-20 Sanofi Pyridyl-vinyl-pyrazolo-chinoline als par1-inhibitoren
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
WO2015013083A1 (en) 2013-07-22 2015-01-29 Merck Sharp & Dohme Corp. Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin
US9808473B2 (en) 2013-08-22 2017-11-07 Merck Sharp & Dohme Corp. Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US20160200715A1 (en) 2013-08-22 2016-07-14 Merck Sharp & Dohme Corp. Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US9701669B2 (en) 2013-08-22 2017-07-11 Merck Sharp & Dohme Corp. Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
JPWO2016114386A1 (ja) * 2015-01-15 2017-10-19 国立研究開発法人国立精神・神経医療研究センター 進行型免疫性脱髄疾患治療剤
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000229961A (ja) * 1998-12-11 2000-08-22 Sagami Chem Res Center ヒドロナフト［２，３−ｃ］フラン誘導体およびその製造方法
TWI236476B (en) * 1997-11-25 2005-07-21 Schering Corp Thrombin receptor antagonists
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
AU6690001A (en) 2000-06-15 2001-12-24 Schering Corp Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
KR100960170B1 (ko) * 2001-10-18 2010-05-26 쉐링 코포레이션 트롬빈 수용체 길항제로서의 힘바신 동족체
JP4558331B2 (ja) * 2002-04-16 2010-10-06 シェーリング コーポレイション 三環式トロンビンレセプターアンタゴニスト
MY143987A (en) * 2004-05-28 2011-07-29 Schering Corp Constrained himbacine analogs as thrombin receptor antagonists
WO2006076565A2 (en) * 2005-01-14 2006-07-20 Schering Corporation Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
EP2206697B1 (en) * 2005-01-14 2011-10-26 Schering Corporation Exo- and diastereo-selective syntheses of himbacine analogs
CN101137636A (zh) * 2005-01-14 2008-03-05 先灵公司 Himbacine类似物的外型选择性合成
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs

Also Published As

Publication number Publication date
WO2005030712A8 (en) 2007-12-21
RU2367660C2 (ru) 2009-09-20
US20090076088A1 (en) 2009-03-19
ZA200602448B (en) 2007-09-26
RU2006113638A (ru) 2007-11-10
JP4694490B2 (ja) 2011-06-08
AR045809A1 (es) 2005-11-16
WO2005030712A2 (en) 2005-04-07
US7488742B2 (en) 2009-02-10
AU2004276327A1 (en) 2005-04-07
ECSP066455A (es) 2006-09-18
CA2540163A1 (en) 2005-04-07
CN101128457A (zh) 2008-02-20
MY143834A (en) 2011-07-15
WO2005030712A3 (en) 2007-09-20
EP1663965A2 (en) 2006-06-07
EP1663965B1 (en) 2014-04-09
MXPA06003379A (es) 2006-06-08
RU2367660C9 (ru) 2010-08-10
NO20061797L (no) 2006-05-19
PE20050471A1 (es) 2005-08-24
TWI331608B (en) 2010-10-11
CA2540163C (en) 2012-06-05
IL174538A0 (en) 2006-08-01
US20040152736A1 (en) 2004-08-05
KR20060128848A (ko) 2006-12-14
JP2007523051A (ja) 2007-08-16
SG147466A1 (en) 2008-11-28
US20090069383A1 (en) 2009-03-12
TW200524914A (en) 2005-08-01
CO5680428A2 (es) 2006-09-29
AU2004276327B2 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
CR8475A (es) Fenilalanina-amidas sustituidas por benzoilo
CY1112011T1 (el) Παραγωγα αζαδικυκλο (3.1.0) εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
SG147466A1 (en) Thrombin receptor antagonists
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
UY28290A1 (es) Compuestos farmacéuticos novedosos
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
DK1379239T3 (da) N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
ATE340795T1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
TW200745056A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
TW200613256A (en) Photoactive compounds
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
BRPI0417950A (pt) composições farmacêuticas
EP1617806A4 (en) SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MODULATORS
CY1107101T1 (el) Μεθοδος συνθεσης παραγωγων της 1,3-διϋδρο-2h-3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης με φαρμακευτικως αποδεκτο οξυ
BR0307156A (pt) Derivado de pirimidina bicìclica fundida, composto, antagonistas de receptores e agentes profiláticos e terapêuticos
ATE282041T1 (de) Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
EA200400822A1 (ru) Производные 3,4-дигидро-1h-изохинолин-2-ила
ATE390427T1 (de) Diazabicylononan - und decanderivate und ihre verwendung als opioid-rezeptorligande
DK1496059T3 (da) Kondenseret bicyklisk pyrimidinderivat

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2168 DE 24/07/2012.